

**Embassy of India**  
**Santiago**

\*\*\*

**Draft Remarks of Ambassador Abhilasha Joshi on the occasion of the**  
**Inauguration Ceremony of India-Chile Pharmaceutical Business**  
**Forum and B2B Meet**

Distinguished guests,

**Mr. Jorge Canales**, Head of the National Medicines Agency (ANAMED),

**Mr. Jaime Espina**, National Director of CENABAST,

Esteemed representatives from **SUBREI** and **CAMINDIA**,

Shri K Raja Bhanu, Director General of **Pharmexcil** and the accompanying Indian delegation,

My colleagues from the Embassy of India,

Ladies and Gentlemen,

It is my distinct pleasure to welcome you to the India-Chile Pharmaceutical Business Forum. This event reflects the growing strategic importance of pharmaceuticals in our bilateral relationship and our shared commitment to strengthening access to affordable, high-quality healthcare.

India is today the **world's third-largest pharmaceutical producer** by volume and fourteenth by value, with more than **3,000 companies**, **10,500 manufacturing units** and over **60,000 generic brands** across **60 therapeutic areas**. Indian medicines reach over **200 markets** worldwide. With the highest number of USFDA and WHO-GMP certified facilities, more than **60% of our pharma**

**exports go to stringent regulatory destinations.** Today, **United States** accounts for about **34%**, while **Europe** accounts for around **19%** of India's pharmaceutical exports.

Beyond generics, India is also a global leader in **affordable vaccines**: 60% of UNICEF's vaccines are supplied by Indian companies, 99% of WHO's DPT vaccines demand and over 80% of antiretroviral drugs used globally to combat AIDs, are met by Indian manufacturers. During Covid, India gifted medicines and vaccines to more than 90 countries of the Global South, emerging as the trusted Pharmacy to the World.

This global strength is clearly reflected in India's partnership with Chile. India has emerged as Chile's top pharmaceutical partner, accounting for **13.6%** of Chile's pharmaceutical imports, overtaking traditional suppliers such as **US** and **Germany**. In 2025, Chile imported **\$216 million USD** in pharmaceuticals from India. Our pharmaceutical cooperation forms part of the broader momentum in India-Chile relations. President **Gabriel Boric's State visit** to India in April 2025 marked an important milestone, reaffirming our shared commitment to deepening economic and health cooperation.

Ladies and Gentlemen,

Indian pharmaceutical companies have also established a strong and sustained presence in the Chilean market. Well-recognized firms such as **Dr. Reddy's Laboratories, MSN Laboratories, Seven Pharma, SIRON Pharma, Emcure Pharmaceuticals, Ascend Laboratories, Caplin Point Laboratories, Alembic PharmaService**, among others, supply a

wide range of high-quality generic medicines and specialized products. These companies are integrated into both Chile's public and private healthcare supply chains and play an important role in ensuring continuity and affordability of essential medicines.

Moreover, Chile's centralized public procurement system, particularly through **CENABAST**, has been instrumental in expanding access to medicines while ensuring quality and supply security. Indian companies, with their WHO-GMP, EU-GMP and US-FDA compliant facilities, are well positioned to support Chile's public health objectives, especially in high-volume generic medicines critical for public healthcare delivery. Regulatory cooperation is equally important and there is need for greater engagement between **ANAMED** and India's regulatory authorities, for strengthening mutual understanding and facilitating smoother market entry while upholding the highest standards of patient safety. Recognition of Indian Pharmacopoeia would go a long way in further boosting this sector.

Friends,

I would also like to acknowledge the sustained efforts of **Pharmexcil**, which has engaged Chile through multiple business delegations and B2B interactions. These initiatives have laid a strong foundation for long-term commercial partnerships and are further strengthened through the **iPHEX LATAM 2026** engagement. The Indian business delegation comprises over **80 companies** and will engage in the manufacture and export of **generic formulations, active pharmaceutical ingredients, biosimilars, oncology products, injectables and contract manufacturing services**, among many others. The visit builds on

previous iPHEX-LATAM engagements, in which Chile has emerged as a key gateway market for the Southern Cone.

As India remains committed to being a dependable partner for Chile, supporting healthcare systems, strengthening supply security and ensuring access to affordable, high-quality medicines, I wish the forum every success and look forward to productive outcomes from today's discussions and multiple B2B meetings.

Thank you.